FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017433090> ?p ?o ?g. }

• W2017433090 endingPage "2942" @default.
• W2017433090 startingPage "2936" @default.
• W2017433090 abstract "Trials have shown superiority of aromatase inhibitors (AIs) over tamoxifen for post-menopausal oestrogen receptor-positive advanced breast cancer (ER + ABC). We previously reported the use of goserelin plus anastrozole (G + A) as second-line endocrine therapy for pre-menopausal ER + ABC. We report clinical and endocrine data from G + A as first-line systemic therapy. Thirty-six patients (median age = 44 years) with metastatic (N = 28) and locally advanced disease were administered G + A for ⩾6 months (unless progressed prior). Some (N = 13) received further therapy with goserelin plus another AI (steroidal), exemestane (G + E). Serial serum hormone assays (oestradiol, dehydroepiandrosterone sulphate, testosterone, follicle stimulating hormone and luteinising hormone) were performed. Twenty-four patients (67%) derived clinical benefit (CB) (5% complete response, 31% partial response, 31% stable disease for ⩾6 months) with median time to progression and duration of CB of 12 (2–47) and 24 + (7–78+) months respectively. Ten patients were still receiving first-line G + A at analysis. Amongst 13 patients who went onto receive G + E, 38% achieved CB with a mean duration of 13+(7–32) months. Therapy was well tolerated with no withdrawals. The combination of G + A resulted in 98% reduction (from pre-treatment to 6-month) in median levels of oestradiol (from 574.5 pmol/L; inter-quartile range (IQR) = 209–1426; (N = 6) to 13.45 pmol/L; IOQ = 5.5–31.5 (N = 4) whilst the levels of other hormones had minimal fluctuations during therapy. The combinations of ovarian function suppression (using G) and AIs produce sustained CB and minimal side effects in pre-menopausal ER + ABC with significant reduction in oestradiol levels. Within the limitations of being a non-randomised study, they should be considered in appropriate patients with hormone-sensitive ABC." @default.
• W2017433090 created "2016-06-24" @default.
• W2017433090 creator A5005050042 @default.
• W2017433090 creator A5015505200 @default.
• W2017433090 creator A5027058511 @default.
• W2017433090 creator A5057689412 @default.
• W2017433090 creator A5062620682 @default.
• W2017433090 creator A5073889721 @default.
• W2017433090 date "2010-11-01" @default.
• W2017433090 modified "2023-10-16" @default.
• W2017433090 title "Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women" @default.
• W2017433090 cites W1491616134 @default.
• W2017433090 cites W1802889850 @default.
• W2017433090 cites W1829247853 @default.
• W2017433090 cites W1918073772 @default.
• W2017433090 cites W1932574503 @default.
• W2017433090 cites W1964458362 @default.
• W2017433090 cites W2005968088 @default.
• W2017433090 cites W2014783515 @default.
• W2017433090 cites W2040168964 @default.
• W2017433090 cites W2058681718 @default.
• W2017433090 cites W2065118889 @default.
• W2017433090 cites W2085481633 @default.
• W2017433090 cites W2122095366 @default.
• W2017433090 cites W2132846837 @default.
• W2017433090 cites W2148096512 @default.
• W2017433090 cites W3162684029 @default.
• W2017433090 cites W4249367441 @default.
• W2017433090 doi "https://doi.org/10.1016/j.ejca.2010.08.005" @default.
• W2017433090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20832294" @default.
• W2017433090 hasPublicationYear "2010" @default.
• W2017433090 type Work @default.
• W2017433090 sameAs 2017433090 @default.
• W2017433090 citedByCount "35" @default.
• W2017433090 countsByYear W20174330902012 @default.
• W2017433090 countsByYear W20174330902013 @default.
• W2017433090 countsByYear W20174330902014 @default.
• W2017433090 countsByYear W20174330902015 @default.
• W2017433090 countsByYear W20174330902016 @default.
• W2017433090 countsByYear W20174330902017 @default.
• W2017433090 countsByYear W20174330902018 @default.
• W2017433090 countsByYear W20174330902019 @default.
• W2017433090 countsByYear W20174330902020 @default.
• W2017433090 countsByYear W20174330902021 @default.
• W2017433090 countsByYear W20174330902022 @default.
• W2017433090 countsByYear W20174330902023 @default.
• W2017433090 crossrefType "journal-article" @default.
• W2017433090 hasAuthorship W2017433090A5005050042 @default.
• W2017433090 hasAuthorship W2017433090A5015505200 @default.
• W2017433090 hasAuthorship W2017433090A5027058511 @default.
• W2017433090 hasAuthorship W2017433090A5057689412 @default.
• W2017433090 hasAuthorship W2017433090A5062620682 @default.
• W2017433090 hasAuthorship W2017433090A5073889721 @default.
• W2017433090 hasConcept C121608353 @default.
• W2017433090 hasConcept C126322002 @default.
• W2017433090 hasConcept C134018914 @default.
• W2017433090 hasConcept C143998085 @default.
• W2017433090 hasConcept C2775860665 @default.
• W2017433090 hasConcept C2776166826 @default.
• W2017433090 hasConcept C2776215463 @default.
• W2017433090 hasConcept C2777176818 @default.
• W2017433090 hasConcept C2778043895 @default.
• W2017433090 hasConcept C2778504769 @default.
• W2017433090 hasConcept C2779279991 @default.
• W2017433090 hasConcept C29456083 @default.
• W2017433090 hasConcept C530470458 @default.
• W2017433090 hasConcept C71924100 @default.
• W2017433090 hasConceptScore W2017433090C121608353 @default.
• W2017433090 hasConceptScore W2017433090C126322002 @default.
• W2017433090 hasConceptScore W2017433090C134018914 @default.
• W2017433090 hasConceptScore W2017433090C143998085 @default.
• W2017433090 hasConceptScore W2017433090C2775860665 @default.
• W2017433090 hasConceptScore W2017433090C2776166826 @default.
• W2017433090 hasConceptScore W2017433090C2776215463 @default.
• W2017433090 hasConceptScore W2017433090C2777176818 @default.
• W2017433090 hasConceptScore W2017433090C2778043895 @default.
• W2017433090 hasConceptScore W2017433090C2778504769 @default.
• W2017433090 hasConceptScore W2017433090C2779279991 @default.
• W2017433090 hasConceptScore W2017433090C29456083 @default.
• W2017433090 hasConceptScore W2017433090C530470458 @default.
• W2017433090 hasConceptScore W2017433090C71924100 @default.
• W2017433090 hasIssue "16" @default.
• W2017433090 hasLocation W20174330901 @default.
• W2017433090 hasLocation W20174330902 @default.
• W2017433090 hasOpenAccess W2017433090 @default.
• W2017433090 hasPrimaryLocation W20174330901 @default.
• W2017433090 hasRelatedWork W1491737910 @default.
• W2017433090 hasRelatedWork W1966100371 @default.
• W2017433090 hasRelatedWork W1972662668 @default.
• W2017433090 hasRelatedWork W1992980782 @default.
• W2017433090 hasRelatedWork W2003583183 @default.
• W2017433090 hasRelatedWork W2015807835 @default.
• W2017433090 hasRelatedWork W2019019592 @default.
• W2017433090 hasRelatedWork W2090744251 @default.
• W2017433090 hasRelatedWork W2123746076 @default.
• W2017433090 hasRelatedWork W4385199929 @default.
• W2017433090 hasVolume "46" @default.
• W2017433090 isParatext "false" @default.

• next